Inflation, Supply Chain And Private Label Pressures: Consumer Health Leaders Talk ‘Big Picture’ Challenges

OTC drug and dietary supplement companies continue to face significant economic and competitive issues in what continues to be a highly volatile operating environment. Here we’ve culled takes from top execs at Sanofi, Bayer, J&J, P&G and other leading players, provided during recent sales and earnings presentations.

Positive, young woman looking through a spyglass in front of a blackboard as a crossroad arrows splitted in three different ways. Choosing between up, down and ahead. Difficult decision concept.
• Source: Shutterstock

Lots of talk of macroeconomic headwinds in consumer health companies' quarterly earnings calls of late. CEOs and other top execs at Sanofi, Bayer, Reckitt, Prestige Consumer Healthcare, Johnson & Johnson, Procter & Gamble, Abbott, Church & Dwight, Herbalife, and Bausch & Lomb provided commentary on challenges and what lies ahead. Highlights compiled by HBW Insight.

Julie van

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Ceres Pharma Acquires Belgian Probiotics Player Vésale

 
• By 

Deal adds to Ceres' portfolio probiotic supplements in categories such as women's health and immunity marketed in Europe, Asia and North America.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

 
• By 

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By 

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

Nestlé Health Science’s US VMS Recovery Stutters

 
• By 

US dietary supplement brand Nature's Bounty is yet to fully recover sales since supply issues forced it off shelves last year, according to Nestle's Q1 report.

More from Business

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By 

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

US Consumer Health Market People News: Niagen, INW, Hims & Hers, NOW, Tranont, More

 

Amazon executive moves Hims & Hers; INW Manufacturing adds IPA board member as CSO; USC Gerontology School dean joins Niagen advisory board; ‘Be You, NOW’ campaign during Women’s Health Month; direct seller Tranont expands advisory board; Vitamin Shoppe, sports nutrition brands support Team Red, White & Blue cross-US runners; and Powerade supports Morgan's Message.

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.